All
Ensuring that developing countries have access to new healthcare products: the role of product development partnerships.
Brooks A.D., Wells W.A., McLean T.D., Khanna R., Coghlan R., Mertenskoetter T., Privor-Dumm L.A., Krattiger A., Mahoney R.T. Innovation Strategy Today 3, no. 1(January 2010): 1-5. More »
Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women.
Nel A., Smythe S., Young K., Malcolm K., McCoy C., Rosenberg Z., Romano J. Journal of Acquired Immune Deficiency Syndromes 51, no. 4 (August 2009): 416-23 More »
Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy HIV-negative women.
Nel A.M., Coplan P., van de Wijgert J.H., Kapiga S.H., von Mollendorf C., Geubbels E., Vyankandondera J., Rees H.V., Masenga G., Kiwelu I., Moyes J., Smythe S.C. AIDS 23, no. 12 (July 2009): 1531-8. More »
Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring.
Romano J., Variano B., Coplan P., Van Roey J., Douville K., Rosenberg Z., Temmerman M., Verstraelen H., Van Bortel L., Weyers S., Mitchnick M. AIDS Research and Human Retroviruses 25, no. 5 (2009):... More »
Inhibition of HIV-1 infection by the candidate microbicide, dapivirine, a nonnucleoside reverse transcriptase inhibitor.
Fletcher P., Harman S., Azijn H., Armanasco N., Manlow P., Perumal D., de Bethune M-P., Nuttall J., Romano J., Shattock R. Antimicrobial Agents and Chemotherapy 53, no. 2 (2009):487-95. More »